The nuclear factor erythroid 2-related factor 2/p53 axis in breast cancer

被引:20
作者
Xia, Lei [1 ]
Ma, Wenbiao [1 ]
Afrashteh, Ahmad [2 ]
Sajadi, Mir Amirhossein [3 ]
Fakheri, Hadi [3 ]
Valilo, Mohammad [4 ]
机构
[1] Qinghai Prov Peoples Hosp, Surg Oncol Ward 2, Xining, Qinghai, Peoples R China
[2] Tabriz Univ Med Sci, Dept Periodont, Fac Dent, Tabriz, Iran
[3] Tabriz Univ Med Sci, Paramed Fac, Tabriz, Iran
[4] Urmia Univ Med Sci, Dept Biochem, Fac Med, Orumiyeh, Iran
关键词
breast cancer; drug resistance; Kelch-like ECH-associated protein 1 (Keap1); nuclear factor erythroid 2-related factor 2 (Nrf2); p53; OXIDATIVE STRESS; TP53; MUTATIONS; P53; PROTEIN; MUTANT P53; CONFERS CHEMORESISTANCE; SIGNALING PATHWAY; GENE-EXPRESSION; CELL-SURVIVAL; RISK-FACTORS; DUAL ROLES;
D O I
10.11613/BM.2023.030504
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
One of the most important factors involved in the response to oxidative stress (OS) is the nuclear factor erythroid 2-related factor 2 (Nrf2), which regulates the expression of components such as antioxidative stress proteins and enzymes. Under normal conditions, Kelch- like ECH-associated protein 1 (Keap1) keeps Nrf2 in the cytoplasm, thus preventing its translocation to the nucleus and inhibiting its role. It has been established that Nrf2 has a dual function; on the one hand, it promotes angiogenesis and cancer cell metastasis while causing resistance to drugs and chemotherapy. On the other hand, Nrf2 increases expression and proliferation of glutathione to protect cells against OS. p53 is a tumour suppressor that activates the apoptosis pathway in aging and cancer cells in addition to stimulating the glutaminolysis and antioxidant pathways. Cancer cells use the antioxidant ability of p53 against OS. Therefore, in the present study, we discussed function of Nrf2 and p53 in breast cancer (BC) cells to elucidate their role in protection or destruction of cancer cells as well as their drug resistance or antioxidant properties.
引用
收藏
页数:13
相关论文
共 118 条
  • [1] Ahmad A., 2019, Breast Cancer Metastasis and Drug Resistance, V1152, DOI DOI 10.1007/978-3-030-20301-6
  • [2] The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis
    Almeida, Micaela
    Soares, Mafalda
    Ramalhinho, Ana Cristina
    Moutinho, Jose Fonseca
    Breitenfeld, Luiza
    Pereira, Luisa
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (03) : 523 - 532
  • [3] Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent
    Alwi, Sharifah S. Syed
    Cavell, Breeze E.
    Donlevy, Alison
    Packham, Graham
    [J]. CELL STRESS & CHAPERONES, 2012, 17 (05) : 529 - 538
  • [4] BRCA1 induces antioxidant gene expression and resistance to oxidative stress
    Bae, I
    Fan, S
    Meng, QH
    Rih, JK
    Kim, HJ
    Kang, HJ
    Xu, JW
    Goldberg, ID
    Jaiswal, AK
    Rosen, EM
    [J]. CANCER RESEARCH, 2004, 64 (21) : 7893 - 7909
  • [5] The Function of Autophagy in the Initiation, and Development of Breast Cancer
    Beilankouhi, Elmira Aboutalebi Vand
    Valilo, Mohammad
    Dastmalchi, Narges
    Teimourian, Shahram
    Safaralizadeh, Reza
    [J]. CURRENT MEDICINAL CHEMISTRY, 2024, 31 (20) : 2974 - 2990
  • [6] Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance
    Bekele, Raie T.
    Venkatraman, Ganesh
    Liu, Rong-Zong
    Tang, Xiaoyun
    Mi, Si
    Benesch, Matthew G. K.
    Mackey, John R.
    Godbout, Roseline
    Curtis, Jonathan M.
    McMullen, Todd P. W.
    Brindley, David N.
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [7] Mitochondrial reactive oxygen species trigger hypoxia-inducible factor-dependent extension of the replicative life span during hypoxia
    Bell, Eric L.
    Klimova, Tatyana A.
    Eisenbart, James
    Schumacker, Paul T.
    Chandel, Navdeep S.
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (16) : 5737 - 5745
  • [8] Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status
    Bouchalova, Pavla
    Nenutil, Rudolf
    Muller, Petr
    Hrstka, Roman
    Appleyard, M. Virginia
    Murray, Karen
    Jordan, Lee B.
    Purdie, Colin A.
    Quinlan, Philip
    Thompson, Alastair M.
    Vojtesek, Borivoj
    Coates, Philip J.
    [J]. JOURNAL OF PATHOLOGY, 2014, 233 (03) : 238 - 246
  • [9] NRF2 as a Therapeutic Target in Neurodegenerative Diseases
    Brandes, Mikah S.
    Gray, Nora E.
    [J]. ASN NEURO, 2020, 12
  • [10] Disruption of p53 in human cancer cells alters the responses to therapeutic agents
    Bunz, F
    Hwang, PM
    Torrance, C
    Waldman, T
    Zhang, YG
    Dillehay, L
    Williams, J
    Lengauer, C
    Kinzler, KW
    Vogelstein, B
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (03) : 263 - 269